Brain Cancer clinical trials in Idaho

4 actively recruiting brain cancer trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04166409

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT04511013

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05099003

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Idaho:

Massive Bio SYNERGY-AI site — Boise, Idaho

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20